Evidence map›Paper›PMID 36212403›Full record

ArticleFrontiers in oncology2022

Impact of genetic polymorphisms of drug transporters

Anna Marta Madejczyk, Federico Canzian, Joanna Góra-Tybor, Daniele Campa, Tomasz Sacha, Dorota Link-Lenczowska, Izabela Florek, Witold Prejzner, M Całbecka, M Rymko and 3 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 3 countries.

Anna Marta MadejczykDepartment of Hematology, Medical University of Łódź, Łódź, Poland.
Federico CanzianGenomic Epidemiology Group, German Cancer Research Center Deutsche Krebsforschungszentrum (DKFZ), Heidelberg, Germany.
Joanna Góra-TyborDepartment of Hematology, Medical University of Łódź, Łódź, Poland.
Daniele CampaDepartment of Biology, University of Pisa, Pisa, Italy.
Tomasz SachaDepartment of Hematology, Jagiellonian University Medical College, Kraków, Poland.
Dorota Link-LenczowskaDepartment of Hematology, Jagiellonian University Medical College, Kraków, Poland.
Izabela FlorekDepartment of Hematology, Jagiellonian University Medical College, Kraków, Poland.
Witold PrejznerDepartment of Hematology, Medical University of Gdańsk, Gdańsk, Poland.
M CałbeckaDepartment of Hematology, Copernicus Specialist Municipal Hospital, Toruń, Poland.
M RymkoDepartment of Hematology, Copernicus Specialist Municipal Hospital, Toruń, Poland.
M DudzińskiDepartment of Hematology, Teaching Hospital No 1, Rzeszów, Poland.
Magdalena Julita OrzechowskaDepartment of Molecular Carcinogenesis, Chair of Molecular Medicine and Biotechnology, Faculty of Medicine, Medical University of Łódź, Łódź, Poland.
Krzysztof JamroziakDepartment of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, Warsaw, Poland.
Jagiellonian University · PLMedical University of Lodz · PLCopernicus Memorial Hospital · PLGdańsk Medical University · PLHeidelberg University · DEMedical University of Warsaw · PLRzeszów University · PLUniversity of Pisa · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Functional single-nucleotide polymorphisms (SNPs) in genes regulating cellular uptake, elimination, and metabolism of xenobiotics may potentially influence the outcome of chronic myeloid leukemia (CML) patients treated with BCR-ABL1 tyrosine kinase inhibitors (TKI). Dasatinib, a second-generation TKI, is a substrate of the ABC-superfamily xenobiotic transporters ABCB1 (MDR1, Pg-P) and ABCG2 (BCRP). Pregnane X receptor (PXR, NR1I2) and constitutive androstane receptor (CAR, NR1I3) are involved in the control of expression of Aim of the study: In this study, we assessed the impact of inherited variants in Materials and methods: Sixty-one tagging SNPs in Results: We found the associations between SNPs rs7787082 ( Conclusion: Our data suggest that inherited variants in the genes encoding for proteins involved in the transport of xenobiotics may modify the toxicity and efficacy of dasatinib therapy in CML patients.

Indexed as

ABCB1ABCG2CARChronic myeloid leukemiadasatinibPXRsingle nucleotide polymorphisms

Identifiers

PMID36212403
PMCPMC9537611
OpenAlexW4297003595

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.